Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.071|
|52 Week High||AU$0.062|
|52 Week Low||AU$0.23|
|1 Month Change||5.97%|
|3 Month Change||-17.44%|
|1 Year Change||-8.97%|
|3 Year Change||73.18%|
|5 Year Change||n/a|
|Change since IPO||-55.63%|
Recent News & Updates
We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Imagion...
Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...
|IBX||AU Medical Equipment||AU Market|
Return vs Industry: IBX underperformed the Australian Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: IBX underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: IBX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IBX's weekly volatility (11%) has been stable over the past year.
About the Company
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer.
Imagion Biosystems Fundamentals Summary
|IBX fundamental statistics|
Is IBX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IBX income statement (TTM)|
|Cost of Revenue||AU$2.30m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0049|
|Net Profit Margin||-160.36%|
How did IBX perform over the long term?See historical performance and comparison
Is Imagion Biosystems undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IBX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IBX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IBX is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: IBX is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IBX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IBX is overvalued based on its PB Ratio (5.5x) compared to the AU Medical Equipment industry average (4.5x).
How is Imagion Biosystems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Imagion Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Imagion Biosystems performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IBX is currently unprofitable.
Growing Profit Margin: IBX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IBX is unprofitable, but has reduced losses over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare IBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: IBX has a negative Return on Equity (-37.3%), as it is currently unprofitable.
How is Imagion Biosystems's financial position?
Financial Position Analysis
Short Term Liabilities: IBX's short term assets (A$14.4M) exceed its short term liabilities (A$1.1M).
Long Term Liabilities: IBX's short term assets (A$14.4M) exceed its long term liabilities (A$40.0K).
Debt to Equity History and Analysis
Debt Level: IBX is debt free.
Reducing Debt: IBX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IBX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IBX has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 8.2% each year.
What is Imagion Biosystems's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IBX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IBX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IBX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bob Proulx (63 yo)
Mr. Robert Romeo Proulx, also known as Bob, has been Chief Executive Officer at Imagion Biosystems Limited since January 12, 2015 and has been its President since February 2015. He serves as Executive Chai...
CEO Compensation Analysis
Compensation vs Market: Bob's total compensation ($USD450.96K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.
Experienced Management: IBX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: IBX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.
Imagion Biosystems Limited's employee growth, exchange listings and data sources
- Name: Imagion Biosystems Limited
- Ticker: IBX
- Exchange: ASX
- Founded: 2016
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$74.294m
- Shares outstanding: 1.05b
- Website: https://imagionbiosystems.com
- Imagion Biosystems Limited
- 10355 Science Center Drive
- Suite 210
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:33|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.